글로벌 전립선암 진단 시장 (2023-2030) : 예비, 확증

■ 영문 제목 : Prostate Cancer Diagnostics Market By Test Type (Preliminary, Confirmatory), By Type (Adenocarcinoma, Interstitial cell carcinoma), By End Use (Hospitals, Outpatient Facilities), By Region And Segment Forecasts, 2023 - 2030

Grand View Research가 발행한 조사보고서이며, 코드는 GRV23NOV181 입니다.■ 상품코드 : GRV23NOV181
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 9월
■ 페이지수 : 95
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 임상 진단
■ 판매가격 / 옵션 (부가세 10% 별도)
Single User (1인 열람용)USD5,950 ⇒환산₩8,032,500견적의뢰/주문/질문
Multi User (5인 열람용)USD6,950 ⇒환산₩9,382,500견적의뢰/주문/질문
Global/corporate License (기업 열람용)USD8,950 ⇒환산₩12,082,500견적의뢰/구입/질문
가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
글로벌 전립선암 진단 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 전립선암 진단 시장 규모는 2023년부터 2030년까지 연평균 6. 23%의 성장률로 확대되어 2030년에는 131억 6천만 달러에 달할 것으로 예상됩니다. 정부 지원 정책, 세계 질병 유병률 증가, 확인 진단 검사의 기술 발전과 함께 전립선암 유병률 증가가 이 시장의 주요 촉진 요인입니다.

효과적인 진단 및 치료에 초점을 맞춘 연구를 강화하기 위한 정부의 적극적인 이니셔티브의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 국립암연구소는 '아프리카계 남성의 전립선암에 대한 연구'라는 제목의 연구를 시작했습니다. 이 연구는 아프리카계 미국인 남성의 전립선암과 관련된 비생물학적 및 생물학적 요인을 연구하는 가장 큰 규모의 공동 연구입니다. 이 연구는 National Institute on Minority Health and NCI and Health Disparities가 Prostate Cancer Foundation과 공동으로 시작했으며, 2,600만 달러의 자금이 지원됐습니다.

노퍽 대학과 이스트 앵글리아 대학의 연구진과 노리치 대학 병원은 진단 후 5년 이내에 치료 절차가 필요할 가능성이 최대 8배 낮은 남성을 식별하는 데 도움이 되는 비침습적 소변 검사를 개발했습니다. 이러한 기술 발전은 가까운 장래에 시장 잠재력에도 영향을 미칠 것으로 예상됩니다.

또한 카롤린스카 연구소와 KTH 연구소의 연구원들은 공간 전사체학에 인공지능을 사용하면 전립선암을 조기에 발견하여 임상 진단과 치료를 개선하는 데 도움이 될 수 있다고 결론을 내렸습니다. 공간 전사체학은 일반적으로 활성 유전자와 그 조직형의 정량적 분석을 결합하여 효과적인 질병 진단에 도움이 되는 방법입니다.

전립선암 진단 시장 보고서 하이라이트

- 2022년 시장 점유율은 확인 검사가 가장 큰 비중을 차지했습니다. 이 부문은 66. 31%로 가장 큰 시장 점유율을 기록했습니다. 확진 검사에는 PCA3 검사, 경직장 초음파 검사(TRUS), 환부 생검 등이 포함됩니다.

- 최종 용도에 따라 시장은 병원, 외래 환자 시설, 재택 의료, 연구 및 제조로 구분되며, 2022년에는 외래 환자 시설 부문이 시장을 지배할 것으로 예상됩니다. 외래 환자 시설은 인증된 의사의 획득과 경험을 통해 보다 편안한 상담 및 치료 시스템을 혁신하고 개발했습니다.

- 유형별로는 선암, 간질세포암, 기타로 구분되며, 2022년에는 선암 부문이 75. 11%의 시장 점유율로 시장을 지배했습니다. 선암은 선 조직에 발생하는 암입니다.

- 유병률 증가와 진단 강화를 위한 정부 이니셔티브 증가로 인해 북미 지역이 가장 큰 시장 점유율을 차지하고 있다고 전했습니다.
■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변동, 동향, 범위
Chapter 4. 세계의 전립선암 진단 시장 : 검사 유형별 예측 및 동향 분석
Chapter 5. 세계의 전립선암 진단 시장 : 유형별 예측 및 동향 분석
Chapter 6. 세계의 전립선암 진단 시장 : 최종 용도별 예측 및 동향 분석
Chapter 7. 세계의 전립선암 진단 시장 : 지역별 예측 및 동향 분석
Chapter 8. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Test Type
1.1.2. Type
1.1.3. End-user
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Snapshot
Chapter 3. Prostate Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of prostate cancer
3.3.1.2. Large presence of geriatric population
3.3.2. Market restraint analysis
3.3.2.1. Online Consulting and Treatment
3.4. Prostate Cancer Diagnostics Market: Business Analysis Tools
3.4.1. Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.4. Market Entry Strategies
Chapter 4. Global Prostate Cancer Diagnostics: Test Type Estimates & Trend Analysis
4.1. Global prostate cancer diagnostics market, test type movement analysis
4.2. Preliminary tests
4.2.1. Preliminary tests for prostate cancer diagnostics market, 2018 – 2030 (USD Million)
4.2.2. PSA tests
4.2.2.1. PSA tests market, 2018 – 2030 (USD Million)
4.2.2.2. Free PSA tests market, 2018 – 2030 (USD Million)
4.2.2.3. Total PSA tests market, 2018 – 2030 (USD Million)
4.2.3. Other preliminary tests
4.2.3.1. Other preliminary tests for prostate cancer diagnostics market, 2018 – 2030 (USD Million)
4.3. Confirmatory tests
4.3.1. Confirmatory tests for prostate cancer diagnostics market, 2018 – 2030 (USD Million)
4.3.2. Pca3 tests
4.3.2.1. Pca3 tests market, 2018 – 2030 (USD Million)
4.3.2.2. Trans-rectal ultrasound market, 2018 – 2030 (USD Million)
4.3.2.3. Biopsy tests market, 2018 – 2030 (USD Million)
Chapter 5. Global prostate cancer diagnostics: Type estimates & trend analysis
5.1. Global prostate cancer diagnostics market, type movement analysis
5.2. Adenocarcinoma
5.2.1. Adenocarcinoma market, 2018 – 2030 (USD Million)
5.3. Interstitial cell carcinoma
5.3.1. Interstitial cell carcinoma market, 2018 – 2030 (USD Million)
5.4. Others
5.4.1. Others market, 2018 – 2030 (USD Million)
Chapter 6. Global prostate cancer diagnostics: end-use Estimates & Trend Analysis
6.1. Global prostate cancer diagnostics market, end-use movement analysis
6.2. Hospitals
6.2.1. Hospitals market, 2018 – 2030 (USD Million)
6.3. Outpatient facilities
6.3.1. Outpatient facilities market, 2018 – 2030 (USD Million)
6.4. Home care
6.4.1. Home care market, 2018 – 2030 (USD Million)
6.5. Research & manufacturing
6.5.1. Research & manufacturing market, 2018 – 2030 (USD Million)
Chapter 7. Prostate cancer diagnostics market: Regional Estimates & Trend Analysis
7.1. Prostate cancer diagnostics market, regional movement analysis
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key country dynamics
7.2.3.2. Target disease prevalence
7.2.3.3. Competitive scenario
7.2.3.4. Regulatory framework
7.2.3.5. U.S. prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key country dynamics
7.2.4.2. Target disease prevalence
7.2.4.3. Competitive scenario
7.2.4.4. Regulatory framework
7.2.4.5. Canada prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.3. UK
7.3.3.1. Key country dynamics
7.3.3.2. Target disease prevalence
7.3.3.3. Competitive scenario
7.3.3.4. Regulatory framework
7.3.3.5. UK prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.4. Germany
7.3.4.1. Key country dynamics
7.3.4.2. Target disease prevalence
7.3.4.3. Competitive scenario
7.3.4.4. Regulatory framework
7.3.4.5. Germany prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.5. France
7.3.5.1. Key country dynamics
7.3.5.2. Target disease prevalence
7.3.5.3. Competitive scenario
7.3.5.4. Regulatory framework
7.3.5.5. France prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.6. Italy
7.3.6.1. Key country dynamics
7.3.6.2. Target disease prevalence
7.3.6.3. Competitive scenario
7.3.6.4. Regulatory framework
7.3.6.5. Italy prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.7. Spain
7.3.7.1. Key country dynamics
7.3.7.2. Target disease prevalence
7.3.7.3. Competitive scenario
7.3.7.4. Regulatory framework
7.3.7.5. Spain prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.8. Denmark
7.3.8.1. Key country dynamics
7.3.8.2. Target disease prevalence
7.3.8.3. Competitive scenario
7.3.8.4. Regulatory framework
7.3.8.5. Denmark prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.9. Sweden
7.3.9.1. Key country dynamics
7.3.9.2. Target disease prevalence
7.3.9.3. Competitive scenario
7.3.9.4. Regulatory framework
7.3.9.5. Sweden prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.3.10. Norway
7.3.10.1. Key country dynamics
7.3.10.2. Target disease prevalence
7.3.10.3. Competitive scenario
7.3.10.4. Regulatory framework
7.3.10.5. Norway prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Key country dynamics
7.4.3.2. Target disease prevalence
7.4.3.3. Competitive scenario
7.4.3.4. Regulatory framework
7.4.3.5. Japan prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.4. China
7.4.4.1. Key country dynamics
7.4.4.2. Target disease prevalence
7.4.4.3. Competitive scenario
7.4.4.4. Regulatory framework
7.4.4.5. China prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.5. India
7.4.5.1. Key country dynamics
7.4.5.2. Target disease prevalence
7.4.5.3. Competitive scenario
7.4.5.4. Regulatory framework
7.4.5.5. India prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Key country dynamics
7.4.6.2. Target disease prevalence
7.4.6.3. Competitive scenario
7.4.6.4. Regulatory framework
7.4.6.5. Australia prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Key country dynamics
7.4.7.2. Target disease prevalence
7.4.7.3. Competitive scenario
7.4.7.4. Regulatory framework
7.4.7.5. Thailand prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.4.8. South Korea
7.4.8.1. Key country dynamics
7.4.8.2. Target disease prevalence
7.4.8.3. Competitive scenario
7.4.8.4. Regulatory framework
7.4.8.5. South Korea prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.5.3. Brazil
7.5.3.1. Key country dynamics
7.5.3.2. Target disease prevalence
7.5.3.3. Competitive scenario
7.5.3.4. Regulatory framework
7.5.3.5. Brazil prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Target disease prevalence
7.5.4.3. Competitive scenario
7.5.4.4. Regulatory framework
7.5.4.5. Mexico prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.5.5. Argentina
7.5.5.1. Key country dynamics
7.5.5.2. Target disease prevalence
7.5.5.3. Competitive scenario
7.5.5.4. Regulatory framework
7.5.5.5. Argentina prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.6.3. South Africa
7.6.3.1. Key country dynamics
7.6.3.2. Target disease prevalence
7.6.3.3. Competitive scenario
7.6.3.4. Regulatory framework
7.6.3.5. South Africa prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.6.4. Saudi Arabia
7.6.4.1. Key country dynamics
7.6.4.2. Target disease prevalence
7.6.4.3. Competitive scenario
7.6.4.4. Regulatory framework
7.6.4.5. Saudi Arabia prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.6.5. UAE
7.6.5.1. Key country dynamics
7.6.5.2. Target disease prevalence
7.6.5.3. Competitive scenario
7.6.5.4. Regulatory framework
7.6.5.5. UAE prostate cancer diagnostics market, 2018 – 2030 (USD Million)
7.6.6. Kuwait
7.6.6.1. Key country dynamics
7.6.6.2. Target disease prevalence
7.6.6.3. Competitive scenario
7.6.6.4. Regulatory framework
7.6.6.5. Kuwait prostate cancer diagnostics market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant’s overview
8.2. Financial performance
8.3. Participant categorization
8.3.1. Market leaders
8.3.2. Prostate cancer diagnostics market share analysis, 2022
8.3.3. Company Profiles
8.3.3.1. MDXHEALTH
8.3.3.2. SIGNATURES
8.3.3.3. GENOMIC HEALTH
8.3.3.4. ABBOTT
8.3.3.5. OPKO HEALTH, INC.
8.3.3.6. Oxford Nanopore Technologies plc.
8.3.3.7. SIEMENS HEALTHCARE GMBH
8.3.3.8. CD Genomics
8.3.3.9. DIASORIN S.P.A.
8.3.3.10. BIOMÉRIEUX SA Overview
8.3.4. Strategy Mapping
8.3.4.1. Expansion
8.3.4.2. Acquisition
8.3.4.3. Collaborations
8.3.4.4. Product/Service Launch
8.3.4.5. Partnerships
8.3.4.6. Others

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global prostate cancer diagnostics market, by region, 2018 - 2030 (USD Million)
Table 4 Global prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 5 Global prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 6 Global prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 7 North America prostate cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 8 North America prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 9 North America prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 10 North America prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 11 U.S. prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 12 U.S. prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 13 U.S. prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 14 Canada prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 15 Canada prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 16 Canada prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 17 Europe prostate cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 18 Europe prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 19 Europe prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 20 Europe prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 21 U.K. prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 22 U.K. prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 23 U.K. prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 24 Germany prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 25 Germany prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 26 Germany prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 27 France prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 28 France prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 29 France prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 30 Italy prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 31 Italy prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 32 Italy prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 33 Spain prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 34 Spain prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 35 Spain prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 36 Denmark prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 37 Denmark prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 38 Denmark prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 39 Sweden prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 40 Sweden prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 41 Sweden prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 42 Norway prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 43 Norway prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 44 Norway prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 45 Asia-Pacific prostate cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 46 Asia-Pacific prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 47 Asia-Pacific prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 48 Asia-Pacific prostate cancer diagnostics market, by end Use, 2018 - 2030 (USD Million)
Table 49 Japan prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 50 Japan prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 51 Japan prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 52 China prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 53 China prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 54 China prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 55 India prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 56 India prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 57 India prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 58 Australia prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 59 Australia prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 60 Australia prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 61 Thailand prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 62 Thailand prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 63 Thailand prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 64 South Korea prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 65 South Korea prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 66 South Korea prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 67 Latin America prostate cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 68 Latin America prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 69 Latin America prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 70 Latin America prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 71 Brazil prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 72 Brazil prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 73 Brazil prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 74 Mexico prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 75 Mexico prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 76 Mexico prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 77 Argentina prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 78 Argentina prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 79 Argentina prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 80 MEA prostate cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 81 MEA prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 82 MEA prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 83 MEA prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 84 South Africa prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 85 South Africa prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 86 South Africa prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 90 UAE prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 91 UAE prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 92 UAE prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 93 Kuwait prostate cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 94 Kuwait prostate cancer diagnostics market, by type, 2018 - 2030 (USD Million)
Table 95 Kuwait prostate cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
※본 조사보고서 [글로벌 전립선암 진단 시장 (2023-2030) : 예비, 확증] (코드 : GRV23NOV181) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 전립선암 진단 시장 (2023-2030) : 예비, 확증] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!